FATE – Fate Therapeutics, Inc.
Float Short %
9.21
Margin Of Safety %
Put/Call OI Ratio
0.17
EPS Next Q Diff
-0.01
EPS Last/This Y
0.49
EPS This/Next Y
-0.01
Price
1.26
Target Price
4.94
Analyst Recom
2
Performance Q
-18.3
Relative Volume
1.6
Beta
2.23
Ticker: FATE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | FATE | 1.005 | 0.21 | 0.70 | 6245 |
| 2025-12-29 | FATE | 0.9955 | 0.22 | 0.58 | 6371 |
| 2025-12-30 | FATE | 0.9765 | 0.22 | 0.04 | 6382 |
| 2025-12-31 | FATE | 0.9838 | 0.22 | 0.25 | 6382 |
| 2026-01-02 | FATE | 0.9843 | 0.26 | 0.65 | 6093 |
| 2026-01-05 | FATE | 1.015 | 0.29 | 0.01 | 6482 |
| 2026-01-06 | FATE | 1.01 | 0.30 | 3.30 | 6424 |
| 2026-01-07 | FATE | 1.1 | 0.30 | 1.42 | 6427 |
| 2026-01-08 | FATE | 1.065 | 0.30 | 0.02 | 6743 |
| 2026-01-09 | FATE | 1.05 | 0.30 | 0.00 | 6786 |
| 2026-01-12 | FATE | 1.075 | 0.30 | 0.50 | 6835 |
| 2026-01-13 | FATE | 1.02 | 0.30 | 1.47 | 6847 |
| 2026-01-14 | FATE | 1.08 | 0.29 | 0.37 | 6949 |
| 2026-01-15 | FATE | 1.045 | 0.30 | 0.56 | 7280 |
| 2026-01-16 | FATE | 1.19 | 0.30 | 0.19 | 7298 |
| 2026-01-20 | FATE | 1.105 | 0.18 | 0.24 | 6359 |
| 2026-01-21 | FATE | 1.18 | 0.18 | 0.05 | 6420 |
| 2026-01-22 | FATE | 1.26 | 0.17 | 0.02 | 6785 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | FATE | 1.01 | 37.6 | - | -1.15 |
| 2025-12-29 | FATE | 1.00 | 37.6 | - | -1.15 |
| 2025-12-30 | FATE | 0.98 | 37.6 | - | -1.15 |
| 2025-12-31 | FATE | 0.98 | 37.6 | - | -1.15 |
| 2026-01-02 | FATE | 0.99 | 37.6 | - | -1.15 |
| 2026-01-05 | FATE | 1.02 | 37.6 | - | -1.15 |
| 2026-01-06 | FATE | 1.01 | 37.6 | - | -1.15 |
| 2026-01-07 | FATE | 1.10 | 37.6 | - | -1.15 |
| 2026-01-08 | FATE | 1.07 | 37.6 | - | -1.15 |
| 2026-01-09 | FATE | 1.05 | 37.6 | - | -1.15 |
| 2026-01-12 | FATE | 1.08 | 37.6 | - | -1.15 |
| 2026-01-13 | FATE | 1.02 | 37.6 | - | -1.15 |
| 2026-01-14 | FATE | 1.08 | 37.6 | - | -1.15 |
| 2026-01-15 | FATE | 1.04 | 37.6 | - | -1.15 |
| 2026-01-16 | FATE | 1.19 | 37.6 | - | -1.15 |
| 2026-01-20 | FATE | 1.11 | 37.6 | - | -1.15 |
| 2026-01-21 | FATE | 1.17 | 37.6 | - | -1.15 |
| 2026-01-22 | FATE | 1.26 | 37.6 | - | -1.15 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | FATE | -0.41 | 0.72 | 8.04 |
| 2025-12-29 | FATE | -0.41 | 0.72 | 8.04 |
| 2025-12-30 | FATE | -0.41 | 0.72 | 8.04 |
| 2025-12-31 | FATE | -0.41 | 0.72 | 8.04 |
| 2026-01-02 | FATE | -0.41 | 0.72 | 8.04 |
| 2026-01-05 | FATE | -0.41 | 0.72 | 8.04 |
| 2026-01-06 | FATE | -0.41 | 0.72 | 8.04 |
| 2026-01-07 | FATE | -0.41 | 0.72 | 8.04 |
| 2026-01-08 | FATE | -0.41 | 0.72 | 8.03 |
| 2026-01-09 | FATE | -0.42 | 0.72 | 8.03 |
| 2026-01-12 | FATE | -0.70 | 0.70 | 8.03 |
| 2026-01-13 | FATE | -0.70 | 0.70 | 9.17 |
| 2026-01-14 | FATE | -0.70 | 0.70 | 9.17 |
| 2026-01-15 | FATE | -0.70 | 0.70 | 9.17 |
| 2026-01-16 | FATE | -0.70 | 0.70 | 9.17 |
| 2026-01-20 | FATE | -0.70 | 1.72 | 9.17 |
| 2026-01-21 | FATE | -0.70 | 1.72 | 9.17 |
| 2026-01-22 | FATE | -0.70 | 1.72 | 9.21 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.27
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
-0.7
Institutional Transactions
1.72
Beta
2.23
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
Fair Value
Quality Score
13
Growth Score
23
Sentiment Score
65
Actual DrawDown %
98.9
Max Drawdown 5-Year %
-99.4
Target Price
4.94
P/E
Forward P/E
PEG
P/S
20.2
P/B
0.62
P/Free Cash Flow
EPS
-1.32
Average EPS Est. Cur. Y
-1.15
EPS Next Y. (Est.)
-1.16
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2187.11
Relative Volume
1.6
Return on Equity vs Sector %
-93.9
Return on Equity vs Industry %
-78
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading